Adherence, Efficacy and Safety of an Insulin Protocol in the Critically Ill: A Prospective Observational Study

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00288743

Enrollment

Registered

2006-02-08

Start date

2002-09-30

Completion date

2002-12-31

Last updated

2007-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically Ill Patients

Brief summary

There is a growing body of evidence in the literature regarding the adverse effects of hyperglycemia in critically ill patients. To target and maintain better blood glucose regulation we implemented an insulin protocol with target blood glucose levels between 81-110 mg/dL.

Interventions

DRUGto implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

Inclusion criteria

* Surgical or medical critically ill patients * An expected ICU-stay of more than 72 hours * Age \> 16 years * Need for insulin therapy * Patients must have an arterial line

Exclusion criteria

* Patients who did not respond to the inclusion criteria * Patients with diabetic ketoacidosis * Cardiac surgical patients * Patients transferred from other hospitals * Other study enrollment

Design outcomes

Primary

Measure	Time frame
To evaluate compliance, efficacy and safety of an insulin protocol, with target glycemia between 81-110 mg/dL in critically ill patients	—

Secondary

Measure	Time frame
To determine potential factors associated with blood glucose control	—

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026